ReviewRenal failure2025
Reproductive dysfunction in hemodialysis: endocrine mechanisms, clinical features, and therapeutic approaches.
Review in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sexual dysfunction and effect on quality of life in chronic kidney disease: a systematic review and meta-analysis.BMC nephrology · 2026Pooled it
- Hyperkisspeptinemia and hypothalamic-pituitary-gonadal axis uncoupling in hemodialysis patients: clinical evidence suggestive of central desensitization.Clinical kidney journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reproductive dysfunction is a near-universal and debilitating complication in patients on maintenance hemodialysis, profoundly impacting quality of life. The core patho-physiology is a 'dual-hit' endocrine collapse, where the uremic milieu causes both central suppression of the hypothalamic-pituitary-gonadal (HPG) axis and peripheral gonadal resistance. In men, this manifests as hypogonadism, with erectile dysfunction serving as a critical sentinel marker for systemic vascular disease. In women, it results in a reversible menopause-like state characterized by anovulation and infertility. While conventional hemodialysis is insufficient to correct these derangements, practical therapeutic strategies can mitigate them. Intensified regimens like nocturnal hemo-dialysis can partially restore fertility and dramatically improve pregnancy outcomes. Targeted pharmacological interventions, including phosphodiesterase-5 inhibitors and hormone replacement therapy, are also effective for specific indications. Kidney transplantation offers the best chance of restoring normal endocrine function. Future directions include novel therapeutics targeting the kisspeptin system and the development of wearable artificial kidneys to provide continuous uremic clearance. This review provides a clinically focused overview of the endocrine mechanisms, features, and management of reproductive dysfunction in hemodialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.